Lisaftoclax

A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-2575) in Combination With Azacitidine (AZA) in Patients With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS) (GLORA-4).

What's the purpose of the trial?

A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.

Trial status

Not yet accepting

Phase

Phase 3

Enrollment

464

Last Updated

2 weeks ago

Am I Eligible

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Azacitidine is a type of chemotherapy called a hypomethylating agent that interferes with the growth and spread of cancer cells in the body.
Lisaftoclax is a BCL-2 inhibitor that is being studied for use in several different cancers.
Placebo is a substance that has no therapeutic effect and can be used as a control in testing new drugs in clinical trials.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Lisaftoclax (APG-2575) combined with Azacitidine

Not yet accepting

Placebo combined with Azacitidine

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.